Other Events ·
Atrium Therapeutics doses first patient in Phase 1/2 Corventis trial for PRKAG2 syndrome
RNAAtrium Therapeutics, Inc.
Atrium Therapeutics announced the dosing of the first patient in its Phase 1/2 Corventis clinical trial evaluating ATR 1072, a lead investigational therapy targeting PRKAG2 syndrome. The open-label study will enroll approximately 37 participants to assess safety and efficacy. Initial proof-of-concept data is expected in the second half of 2027. Atrium Therapeutics operates as a biopharmaceutical company advancing precision cardiology through targeted RNA therapeutics.